valproic acid has been researched along with Parkinson Disease in 33 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Valproic acid is associated with increased risks of tremor and parkinsonism." | 8.31 | A Case of Long-Term Exposure to Valproic Acid Mimicking Tremor-Dominant Parkinson's Disease. ( Fujimoto, S; Kawai, K; Koide, R; Mashiko, T; Sekiguchi, K; Tanaka, R, 2023) |
| "Lithium carbonate was not associated with an increased risk of Parkinson-like events, but was related to these events in patients taking sodium valproate." | 5.72 | Relationship between lithium carbonate and the risk of Parkinson-like events in patients with bipolar disorders: A multivariate analysis using the Japanese adverse drug event report database. ( Nabekura, T; Uwai, Y, 2022) |
| "Myoclonus and seizures disappeared after discontinuation of L-dopa and the introduction of valproate sodium (VPA)." | 5.29 | Myoclonus and seizures in a patient with parkinsonism: induction by levodopa and its confirmation on SEPs. ( Hamada, T; Matsuura, T; Moriwaka, F; Tashiro, K; Yoshida, K, 1993) |
| "Valproic acid is associated with increased risks of tremor and parkinsonism." | 4.31 | A Case of Long-Term Exposure to Valproic Acid Mimicking Tremor-Dominant Parkinson's Disease. ( Fujimoto, S; Kawai, K; Koide, R; Mashiko, T; Sekiguchi, K; Tanaka, R, 2023) |
| "To test the hypothesis of an increased incidence of antiparkinson drug prescribing or Parkinson disease (PD) diagnostic codes after chronic lithium treatment compared with chronic valproic acid or antidepressant treatment among older adults." | 3.83 | Lithium Use in Older Adults is Associated with Increased Prescribing of Parkinson Medications. ( Fischer, HD; Fung, K; Gruneir, A; Herrmann, N; Marras, C; Rej, S; Rochon, PA; Seitz, D; Shulman, KI; Vigod, S, 2016) |
| "We applied valproic acid (VPA) on the rigidity of three parkinsonian patients, two with Parkinson disease and one with striatonigral degeneration." | 3.70 | [Valproic acid relieved marked rigidity in three patients with end-stage parkinsonism]. ( Fujimoto, K; Nakano, I; Sayama, S, 1998) |
| "We made accelerometric recordings of the tremor induced by valproic acid." | 3.66 | Valproate tremors. ( Bauman, AW; Hammond, EJ; Karas, BJ; Wilder, BJ, 1982) |
| "The phenytoin treatment causes cerebellar defect and anemia." | 2.82 | The interplay of epilepsy with impaired mitophagy and autophagy linked dementia (MAD): A review of therapeutic approaches. ( Agrawal, M; Dhurandhar, Y; Panda, SP, 2022) |
| "Among psychiatric disorders the acute symptoms of schizophrenia are exacerbated by enhanced GABA-ergic function." | 2.36 | Pharmacology of GABA. ( Meldrum, B, 1982) |
| "Lithium carbonate was not associated with an increased risk of Parkinson-like events, but was related to these events in patients taking sodium valproate." | 1.72 | Relationship between lithium carbonate and the risk of Parkinson-like events in patients with bipolar disorders: A multivariate analysis using the Japanese adverse drug event report database. ( Nabekura, T; Uwai, Y, 2022) |
| "A novel intrastriatal rotenone model of Parkinson's disease was used to examine the neuroprotective effects of valproic acid (VPA), which is known to upregulate neurotrophic factors and other protective proteins in the brain." | 1.40 | Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease. ( Carriere, CH; Kang, NH; Niles, LP, 2014) |
| "Myoclonus and seizures disappeared after discontinuation of L-dopa and the introduction of valproate sodium (VPA)." | 1.29 | Myoclonus and seizures in a patient with parkinsonism: induction by levodopa and its confirmation on SEPs. ( Hamada, T; Matsuura, T; Moriwaka, F; Tashiro, K; Yoshida, K, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (27.27) | 18.7374 |
| 1990's | 6 (18.18) | 18.2507 |
| 2000's | 1 (3.03) | 29.6817 |
| 2010's | 13 (39.39) | 24.3611 |
| 2020's | 4 (12.12) | 2.80 |
| Authors | Studies |
|---|---|
| Uwai, Y | 1 |
| Nabekura, T | 1 |
| Panda, SP | 1 |
| Dhurandhar, Y | 1 |
| Agrawal, M | 1 |
| Sekiguchi, K | 1 |
| Mashiko, T | 1 |
| Koide, R | 1 |
| Kawai, K | 1 |
| Fujimoto, S | 1 |
| Tanaka, R | 1 |
| Meka, ST | 1 |
| Bojja, SL | 1 |
| Kumar, G | 1 |
| Birangal, SR | 1 |
| Rao, CM | 1 |
| Bolland, MJ | 1 |
| Avenell, A | 1 |
| Gamble, G | 1 |
| Grey, A | 1 |
| Kautu, BB | 1 |
| Carrasquilla, A | 1 |
| Hicks, ML | 1 |
| Caldwell, KA | 1 |
| Caldwell, GA | 1 |
| Carriere, CH | 1 |
| Kang, NH | 1 |
| Niles, LP | 1 |
| Epstein, J | 1 |
| Madiedo, CJ | 1 |
| Lai, L | 1 |
| Hayes, MT | 1 |
| Harrison, IF | 1 |
| Crum, WR | 1 |
| Vernon, AC | 1 |
| Dexter, DT | 1 |
| Marras, C | 1 |
| Herrmann, N | 1 |
| Fischer, HD | 1 |
| Fung, K | 1 |
| Gruneir, A | 1 |
| Rochon, PA | 1 |
| Rej, S | 1 |
| Vigod, S | 1 |
| Seitz, D | 1 |
| Shulman, KI | 1 |
| Zhang, Y | 1 |
| Wu, JY | 1 |
| Weng, LH | 1 |
| Li, XX | 1 |
| Yu, LJ | 1 |
| Xu, Y | 1 |
| Lauterbach, EC | 1 |
| Victoroff, J | 1 |
| Coburn, KL | 1 |
| Shillcutt, SD | 1 |
| Doonan, SM | 1 |
| Mendez, MF | 1 |
| Hicks, CW | 1 |
| Pandya, MM | 1 |
| Itin, I | 1 |
| Fernandez, HH | 1 |
| Schilbach, L | 1 |
| Weiss, PH | 1 |
| Kuhn, J | 1 |
| Timmermann, L | 1 |
| Klosterkötter, J | 1 |
| Huff, W | 1 |
| Xiong, N | 1 |
| Jia, M | 1 |
| Chen, C | 1 |
| Xiong, J | 1 |
| Zhang, Z | 1 |
| Huang, J | 1 |
| Hou, L | 1 |
| Yang, H | 1 |
| Cao, X | 1 |
| Liang, Z | 1 |
| Sun, S | 1 |
| Lin, Z | 1 |
| Wang, T | 1 |
| Chabwine, JN | 1 |
| Rossetti, AR | 1 |
| Hirt, L | 1 |
| Kuntzer, T | 1 |
| Schluep, M | 1 |
| Michel, P | 1 |
| Démonet, JF | 1 |
| du Pasquier, RA | 1 |
| Vingerhoets, FG | 1 |
| Sriram, A | 1 |
| Ward, HE | 1 |
| Hassan, A | 1 |
| Iyer, S | 1 |
| Foote, KD | 1 |
| Rodriguez, RL | 1 |
| McFarland, NR | 1 |
| Okun, MS | 1 |
| Chen, PS | 1 |
| Peng, GS | 1 |
| Li, G | 1 |
| Yang, S | 1 |
| Wu, X | 1 |
| Wang, CC | 1 |
| Wilson, B | 1 |
| Lu, RB | 1 |
| Gean, PW | 1 |
| Chuang, DM | 1 |
| Hong, JS | 1 |
| Meldrum, B | 1 |
| Marsden, CD | 2 |
| Sheehy, MP | 1 |
| Karas, BJ | 1 |
| Wilder, BJ | 1 |
| Hammond, EJ | 1 |
| Bauman, AW | 1 |
| Yoshida, K | 1 |
| Moriwaka, F | 1 |
| Matsuura, T | 1 |
| Hamada, T | 1 |
| Tashiro, K | 1 |
| del Real Francia, MA | 1 |
| Sanz Martínez, J | 1 |
| Vaamonde Gamo, J | 1 |
| Gudín Rodríguez-Magariños, M | 1 |
| Ibáñez Alonso, R | 1 |
| Riñón, V | 1 |
| Armon, C | 1 |
| Shin, C | 1 |
| Miller, P | 1 |
| Carwile, S | 1 |
| Brown, E | 1 |
| Edinger, JD | 1 |
| Paul, RG | 1 |
| Volpi, R | 1 |
| Chiodera, P | 1 |
| Caffarra, P | 1 |
| Scaglioni, A | 1 |
| Saccani, A | 1 |
| Coiro, V | 1 |
| Sayama, S | 1 |
| Fujimoto, K | 1 |
| Nakano, I | 1 |
| Piccinin, GL | 1 |
| Morocutti, C | 1 |
| Urciuoli, R | 1 |
| Bernardi, G | 1 |
| Price, PA | 1 |
| Parkes, JD | 1 |
| Nutt, J | 1 |
| Williams, A | 1 |
| Plotkin, C | 1 |
| Eng, N | 1 |
| Ziegler, M | 1 |
| Calne, DB | 1 |
| Nutt, JG | 1 |
| Kupferberg, HJ | 1 |
| Schobben, F | 1 |
| van der Kleijn, E | 1 |
| Gabreëls, FJ | 1 |
| Clarke, BM | 1 |
| Upton, A | 1 |
| Griffin, H | 1 |
| Hudoba, P | 1 |
| Gram, L | 1 |
| Bentsen, KD | 1 |
4 reviews available for valproic acid and Parkinson Disease
| Article | Year |
|---|---|
The interplay of epilepsy with impaired mitophagy and autophagy linked dementia (MAD): A review of therapeutic approaches.
Topics: Anticonvulsants; Carbamazepine; Dementia; Epilepsy; Felbamate; Gabapentin; Humans; Inflammasomes; La | 2022 |
Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipsychotic Agents; Benzodiazepines; Benzo | 2010 |
Pharmacology of GABA.
Topics: 4-Aminobutyrate Transaminase; Anxiety Disorders; Autonomic Nervous System; Barbiturates; Benzodiazep | 1982 |
Valproate: an updated review.
Topics: Abnormalities, Drug-Induced; Brain Diseases; Chemical and Drug Induced Liver Injury; Coma; Dyskinesi | 1985 |
4 trials available for valproic acid and Parkinson Disease
| Article | Year |
|---|---|
GABA and movement disorders.
Topics: Anticonvulsants; Baclofen; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; | 1981 |
Different control mechanisms of growth hormone (GH) secretion between gamma-amino- and gamma-hydroxy-butyric acid: neuroendocrine evidence in Parkinson's disease.
Topics: Aged; Baclofen; GABA Agents; GABA Agonists; gamma-Aminobutyric Acid; Growth Hormone; Humans; Male; M | 1997 |
Sodium valproate in the treatment of levodopa-induced dyskinesia.
Topics: Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; M | 1978 |
Treatment of Parkinson's disease with sodium valproate: clinical, pharmacological, and biochemical observations.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; g | 1979 |
25 other studies available for valproic acid and Parkinson Disease
| Article | Year |
|---|---|
Relationship between lithium carbonate and the risk of Parkinson-like events in patients with bipolar disorders: A multivariate analysis using the Japanese adverse drug event report database.
Topics: Antimanic Agents; Bipolar Disorder; Drug-Related Side Effects and Adverse Reactions; Humans; Japan; | 2022 |
A Case of Long-Term Exposure to Valproic Acid Mimicking Tremor-Dominant Parkinson's Disease.
Topics: Aged; Humans; Male; Parkinson Disease; Parkinsonian Disorders; Tomography, Emission-Computed, Single | 2023 |
Novel HDAC inhibitors provide neuroprotection in MPTP-induced Parkinson's disease model of rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Histone Dea | 2023 |
Reader response: Expression of Concern: Does compensatory hyperparathyroidism predispose to ischemic stroke? Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy; An alternative to vitamin D supplementation to pre
Topics: Adult; Bone Density; Bone Remodeling; Brain Ischemia; Dietary Supplements; Epilepsy; Humans; Hyperpa | 2018 |
Valproic acid ameliorates C. elegans dopaminergic neurodegeneration with implications for ERK-MAPK signaling.
Topics: alpha-Synuclein; Animals; Anticonvulsants; Caenorhabditis elegans; Caenorhabditis elegans Proteins; | 2013 |
Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dopaminergic Neurons; Functional Laterality; | 2014 |
Successful treatment of dopamine dysregulation syndrome with valproic acid.
Topics: Antimanic Agents; Carbidopa; Compulsive Behavior; Dopamine Agonists; Drug Combinations; Female; Huma | 2014 |
Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors.
Topics: Acetylation; Acetylcysteine; Animals; Behavior, Animal; Brain; Brain-Derived Neurotrophic Factor; Di | 2015 |
Lithium Use in Older Adults is Associated with Increased Prescribing of Parkinson Medications.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Antimanic Agents; Antiparkinson Agents; Dopamine Age | 2016 |
Valproic acid protects against MPP
Topics: 1-Methyl-4-phenylpyridinium; Adenine; Apoptosis; Autophagy; Cell Line, Tumor; Cell Survival; Humans; | 2017 |
Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease.
Topics: Adult; Anticonvulsants; Antiparkinson Agents; Disruptive, Impulse Control, and Conduct Disorders; Hu | 2011 |
Pharmacological treatment of deep brain stimulation-induced hypomania leads to clinical remission while preserving motor benefits.
Topics: Antimanic Agents; Bipolar Disorder; Clozapine; Deep Brain Stimulation; Humans; Male; Middle Aged; Pa | 2012 |
Potential autophagy enhancers attenuate rotenone-induced toxicity in SH-SY5Y.
Topics: Apoptosis; Autophagy; Blotting, Western; Carbamazepine; Cell Line, Tumor; Cell Survival; DNA Fragmen | 2011 |
[Neurology].
Topics: Antibodies, Monoclonal; Anticonvulsants; Atrial Fibrillation; Carbamates; Chronic Disease; Deep Brai | 2012 |
Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Anticonvulsants; Carbidopa; Disruptive, Impulse Co | 2013 |
Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes.
Topics: Animals; Anticonvulsants; Astrocytes; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Cell Comm | 2006 |
Valproate tremors.
Topics: Adolescent; Adult; Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Middle Aged; Parkinson | 1982 |
Myoclonus and seizures in a patient with parkinsonism: induction by levodopa and its confirmation on SEPs.
Topics: Aged; Electroencephalography; Electromyography; Epilepsies, Myoclonic; Epilepsy, Generalized; Evoked | 1993 |
[Parkinsonism induced by sodium valproate].
Topics: Aged; Anticonvulsants; Epilepsy, Tonic-Clonic; Female; Humans; Parkinson Disease; Valproic Acid | 1995 |
Reversible parkinsonism and cognitive impairment with chronic valproate use.
Topics: Adult; Aged; Analysis of Variance; Cognition Disorders; Female; Humans; Male; Middle Aged; Parkinson | 1996 |
[Valproic acid relieved marked rigidity in three patients with end-stage parkinsonism].
Topics: Aged; Female; GABA Agents; Humans; Middle Aged; Muscle Rigidity; Parkinson Disease; Treatment Outcom | 1998 |
[The use of sodium dipropylacetate in the treatment of parkinsonian tremor. Preliminary note].
Topics: Aged; Female; Humans; Male; Middle Aged; Parkinson Disease; Valerates; Valproic Acid | 1977 |
Linear relationship between plasma concentration and dosage of sodium valproate.
Topics: Dose-Response Relationship, Drug; Humans; Parkinson Disease; Valproic Acid | 1979 |
Pharmacokinetics of di-n-propylacetate in epileptic patients.
Topics: Administration, Oral; Aged; Body Weight; Child; Child, Preschool; Dose-Response Relationship, Drug; | 1975 |
Balance and cognitive impairment in two epileptic patients before and after vagal nerve stimulation.
Topics: Adult; Carbamazepine; Cognition; Electric Stimulation Therapy; Epilepsy, Temporal Lobe; Humans; Male | 1991 |